Efficacy and Safety of Cagrilintide-Semaglutide Combination vs Semaglutide Alone for Weight Management in East Asian Adults with Overweight/Obesity: REDEFINE 5 Trial
Posted inDiabetes & Endocrinology news

Efficacy and Safety of Cagrilintide-Semaglutide Combination vs Semaglutide Alone for Weight Management in East Asian Adults with Overweight/Obesity: REDEFINE 5 Trial

Phase 3a trial in Japan/Taiwan shows cagrilintide-semaglutide combination delivers superior weight loss (18.4%) versus semaglutide alone (11.9%) in adults with overweight/obesity ± type 2 diabetes, with comparable safety profiles dominated by manageable gastrointestinal side effects.
Holding GLP-1/GIP Agonists Before Upper Endoscopy Reduces Residual Gastric Volume Risk: Insights from the OCULUS Randomized Trial
Posted inGastroenterology Internal Medicine news

Holding GLP-1/GIP Agonists Before Upper Endoscopy Reduces Residual Gastric Volume Risk: Insights from the OCULUS Randomized Trial

The OCULUS randomized trial demonstrates that continuing GLP-1/GIP agonists before upper endoscopy significantly increases the risk of clinically significant residual gastric volume compared to holding a single dose, providing crucial evidence for perioperative management guidelines.